

Medigen Biotechnology Corp. (3176 MEDIGEN)					
SEQ_NO	2	Date of announcement	2023/03/30	Time of announcement	19:24:02
Subject	The Company's 2022 consolidated financial statements have been reported to the Board of Directors				
Date of events	2023/03/30	To which item it meets	paragraph 31		
Statement	<ol style="list-style-type: none"> 1. Date of the board of directors submitted or approved: 2023/03/30 2. Date of the audit committee approved: 2023/03/30 3. Start and end dates of financial reports or unaudited financial information of the reporting period (XXXX/XX/XX~XXXX/XX/XX): 2022/01/01~2022/12/31 4. Operating revenue accumulated from 1/1 to end of the period (thousand NTD): 1,055,947 5. Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD): 87,460 6. Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD): (1,666,976) 7. Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD): (1,872,613) 8. Profit (loss) accumulated from 1/1 to end of the period (thousand NTD): (1,931,487) 9. Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD): (675,874) 10. Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD): (4.86) 11. Total assets end of the period (thousand NTD): 9,982,274 12. Total liabilities end of the period (thousand NTD): 3,511,261 13. Equity attributable to owners of parent end of the period (thousand NTD): 2,194,027 14. Any other matters that need to be specified: None 				